 SAN CARLOS Calif., July 19, 2021 GLOBE NEWSWIRE -- Atreca, Inc. Atreca NASDAQ: BCEL, a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Dr. Stacey Ma, Executive Vice President and Head of Technical Operations at Sana Biotechnology, and Stephen R. Brady, Chief Executive Officer of Tempest Therapeutics, to its Board of Directors. 